| RS2106341434 |
COL6A3
|
Health Risk |
Likely pathogenic |
Bethlem myopathy 1A, Bethlem myopathy 1A |
| RS2106341460 |
COL6A3
|
Health Risk |
Pathogenic |
Bethlem myopathy 1A, Bethlem myopathy 1A |
| RS2106342311 |
COL6A3
|
Health Risk |
Conflicting classifications of pathogenicity |
Bethlem myopathy 1A, Bethlem myopathy 1A |
| RS2106343198 |
SP110
|
Health Risk |
Pathogenic |
Hepatic veno-occlusive disease-immunodeficiency syndrome, Hepatic veno-occlusive disease-immunodeficiency syndrome |
| RS2106343479 |
COL6A3
|
Health Risk |
Pathogenic |
Bethlem myopathy 1A, Bethlem myopathy 1A |
| RS2106344225 |
COL6A3
|
Health Risk |
Pathogenic |
Bethlem myopathy 1A, Bethlem myopathy 1A |
| RS2106346033 |
SCN9A
|
Health Risk |
Pathogenic |
Generalized epilepsy with febrile seizures plus, type 7 |
| RS2106348112 |
DIS3L2
|
Health Risk |
Pathogenic |
Perlman syndrome, Perlman syndrome |
| RS2106348160 |
DIS3L2
|
Health Risk |
Pathogenic |
Perlman syndrome, Perlman syndrome |
| RS2106348255 |
DIS3L2
|
Health Risk |
Likely pathogenic |
Perlman syndrome, Perlman syndrome |
| RS2106348318 |
SP110
|
Health Risk |
Pathogenic |
Hepatic veno-occlusive disease-immunodeficiency syndrome, Hepatic veno-occlusive disease-immunodeficiency syndrome |
| RS2106350184 |
DIS3L2
|
Health Risk |
Likely pathogenic |
Perlman syndrome, Perlman syndrome |
| RS2106350905 |
COL6A3
|
Health Risk |
Likely pathogenic |
Bethlem myopathy 1A, Bethlem myopathy 1A |
| RS2106353572 |
DIS3L2
|
Health Risk |
Pathogenic |
Perlman syndrome, Perlman syndrome |
| RS2106354296 |
DIS3L2
|
Health Risk |
Pathogenic |
Perlman syndrome, Perlman syndrome |
| RS2106354449 |
DIS3L2
|
Health Risk |
Likely pathogenic |
Perlman syndrome, Perlman syndrome |
| RS2106354681 |
DIS3L2
|
Health Risk |
Likely pathogenic |
Perlman syndrome, Perlman syndrome |
| RS2106355380 |
DIS3L2
|
Health Risk |
Conflicting classifications of pathogenicity |
Perlman syndrome, Perlman syndrome |
| RS2106361236 |
COL6A3
|
Health Risk |
Pathogenic |
Bethlem myopathy 1A, Bethlem myopathy 1A |
| RS2106363697 |
TRAF3IP1
|
Health Risk |
Pathogenic |
— |
| RS2106364423 |
TRAF3IP1
|
Health Risk |
Pathogenic |
— |
| RS2106366689 |
COL6A3
|
Health Risk |
Pathogenic |
Bethlem myopathy 1A, Bethlem myopathy 1A |
| RS2106367443 |
COL6A3
|
Health Risk |
Pathogenic |
Bethlem myopathy 1A, Bethlem myopathy 1A |
| RS2106369643 |
NHEJ1
|
Health Risk |
Likely pathogenic |
Cernunnos-XLF deficiency, Cernunnos-XLF deficiency |
| RS2106383164 |
SCN9A
|
Health Risk |
Likely pathogenic |
Generalized epilepsy with febrile seizures plus, type 7 |
| RS2106387246 |
SCN9A
|
Health Risk |
Pathogenic |
Generalized epilepsy with febrile seizures plus, type 7 |
| RS2106387939 |
COL6A3
|
Health Risk |
Likely pathogenic |
— |
| RS2106388332 |
COL6A3
|
Health Risk |
Pathogenic |
Bethlem myopathy 1A, Bethlem myopathy 1A |
| RS2106395478 |
SCN9A
|
Health Risk |
Likely pathogenic |
Neuropathy, hereditary sensory and autonomic |
| RS2106403305 |
SCN9A
|
Health Risk |
Pathogenic |
Generalized epilepsy with febrile seizures plus, type 7 |
| RS2106426285 |
SCN9A
|
Health Risk |
Pathogenic |
Primary erythromelalgia, Primary erythromelalgia |
| RS2106426576 |
SCN9A
|
Health Risk |
Pathogenic |
Neuropathy, hereditary sensory and autonomic |
| RS2106427278 |
AGXT
|
Health Risk |
Pathogenic |
— |
| RS2106427288 |
AGXT
|
Health Risk |
Likely pathogenic |
Primary hyperoxaluria, type I |
| RS2106427637 |
AGXT
|
Health Risk |
Likely pathogenic |
— |
| RS2106428645 |
AGXT
|
Health Risk |
Pathogenic |
Primary hyperoxaluria, type I |
| RS2106428650 |
AGXT
|
Health Risk |
Conflicting classifications of pathogenicity |
Primary hyperoxaluria, type I |
| RS2106429448 |
AGXT
|
Health Risk |
Likely pathogenic |
Primary hyperoxaluria, type I |
| RS2106429472 |
AGXT
|
Health Risk |
Likely pathogenic |
— |
| RS2106429490 |
AGXT
|
Health Risk |
Likely pathogenic |
— |
| RS2106429906 |
AGXT
|
Health Risk |
Pathogenic |
Primary hyperoxaluria, type I |
| RS2106430885 |
AGXT
|
Health Risk |
Pathogenic |
— |
| RS2106430919 |
AGXT
|
Health Risk |
Pathogenic |
— |
| RS2106430924 |
AGXT
|
Health Risk |
Likely pathogenic |
Primary hyperoxaluria, type I |
| RS2106431706 |
AGXT
|
Health Risk |
Likely pathogenic |
Nephrotic syndrome, Nephrotic syndrome |
| RS2106460925 |
SCN9A
|
Health Risk |
Pathogenic |
Neuropathy, hereditary sensory and autonomic |
| RS2106461311 |
SCN9A
|
Health Risk |
Pathogenic |
Generalized epilepsy with febrile seizures plus, type 7 |
| RS2106469123 |
SCN9A
|
Health Risk |
Pathogenic |
Generalized epilepsy with febrile seizures plus, type 7 |
| RS2106469561 |
SCN9A
|
Health Risk |
Likely pathogenic |
Neuropathy, hereditary sensory and autonomic |
| RS2106471095 |
SCN9A
|
Health Risk |
Pathogenic |
Neuropathy, hereditary sensory and autonomic |
| RS2106479076 |
CYP27A1
|
Health Risk |
Likely pathogenic |
Cholestanol storage disease, Cholestanol storage disease |
| RS2106486889 |
SCN9A
|
Health Risk |
Likely pathogenic |
Generalized epilepsy with febrile seizures plus, type 7 |
| RS2106487245 |
SCN9A
|
Health Risk |
Pathogenic |
Neuropathy, hereditary sensory and autonomic |
| RS2106492882 |
ITPR1
|
Health Risk |
Likely pathogenic |
Gillespie syndrome, Gillespie syndrome |
| RS2106492941 |
ITPR1
|
Health Risk |
Conflicting classifications of pathogenicity |
Spinocerebellar ataxia type 15/16, Spinocerebellar ataxia type 15/16 |
| RS2106493110 |
SCN9A
|
Health Risk |
Pathogenic |
Channelopathy-associated congenital insensitivity to pain, autosomal recessive |
| RS2106494596 |
ITPR1
|
Health Risk |
Likely pathogenic |
Spinocerebellar ataxia type 29, Spinocerebellar ataxia type 29 |
| RS2106506584 |
SCN9A
|
Health Risk |
Pathogenic |
Generalized epilepsy with febrile seizures plus, type 7 |
| RS2106514698 |
FN1
|
Health Risk |
Pathogenic |
— |
| RS2106527836 |
SCN9A
|
Health Risk |
Pathogenic |
Channelopathy-associated congenital insensitivity to pain, autosomal recessive |
| RS2106636277 |
C2orf69
|
Health Risk |
Pathogenic |
Combined oxidative phosphorylation deficiency 53, Combined oxidative phosphorylation deficiency 53 |
| RS2106636278 |
C2orf69
|
Health Risk |
Pathogenic |
Combined oxidative phosphorylation deficiency 53, Combined oxidative phosphorylation deficiency 53 |
| RS2106636543 |
C2orf69
|
Health Risk |
Pathogenic |
Combined oxidative phosphorylation deficiency 53, Combined oxidative phosphorylation deficiency 53 |
| RS2106636544 |
C2orf69
|
Health Risk |
Pathogenic |
Combined oxidative phosphorylation deficiency 53, Combined oxidative phosphorylation deficiency 53 |
| RS2106636545 |
C2orf69
|
Health Risk |
Pathogenic |
Combined oxidative phosphorylation deficiency 53, Combined oxidative phosphorylation deficiency 53 |
| RS2106637622 |
SLC25A20
|
Health Risk |
Likely pathogenic |
Carnitine acylcarnitine translocase deficiency, Carnitine acylcarnitine translocase deficiency |
| RS2106640003 |
CACNA2D2
|
Health Risk |
Pathogenic |
Cerebellar atrophy with seizures and variable developmental delay, Cerebellar atrophy with seizures and variable developmental delay |
| RS2106640384 |
CACNA2D2
|
Health Risk |
Likely pathogenic |
Early-infantile DEE, Early-infantile DEE |
| RS2106642261 |
SETD2
|
Health Risk |
Pathogenic |
Inborn genetic diseases, Inborn genetic diseases |
| RS2106648140 |
ADAMTS9
|
Health Risk |
Likely pathogenic |
Nephronophthisis, Nephronophthisis |
| RS2106652662 |
CACNA2D2
|
Health Risk |
Likely pathogenic |
Early-infantile DEE, Early-infantile DEE |
| RS2106654236 |
CACNA2D2
|
Health Risk |
Likely pathogenic |
Early-infantile DEE, Early-infantile DEE |
| RS2106654966 |
FLNB
|
Health Risk |
Pathogenic |
— |
| RS2106661644 |
CACNA2D2
|
Health Risk |
Likely pathogenic |
Cerebellar atrophy with seizures and variable developmental delay, Cerebellar atrophy with seizures and variable developmental delay |
| RS2106664189 |
CACNA2D2
|
Health Risk |
Pathogenic |
Early-infantile DEE, Early-infantile DEE |
| RS2106672523 |
SLC25A20
|
Health Risk |
Pathogenic |
Carnitine acylcarnitine translocase deficiency, Carnitine acylcarnitine translocase deficiency |
| RS2106675579 |
SETD2
|
Health Risk |
Pathogenic/Likely pathogenic |
— |
| RS2106683989 |
SETD2
|
Health Risk |
Conflicting classifications of pathogenicity |
Luscan-Lumish syndrome, Luscan-Lumish syndrome |
| RS2106685214 |
SMARCC1
|
Health Risk |
Likely pathogenic |
Global developmental delay, Global developmental delay |
| RS2106689406 |
SETD2
|
Health Risk |
Pathogenic |
Luscan-Lumish syndrome, Luscan-Lumish syndrome |
| RS2106702374 |
CACNA2D2
|
Health Risk |
Likely pathogenic |
Early-infantile DEE, Early-infantile DEE |
| RS2106710726 |
SETD2
|
Health Risk |
Likely pathogenic |
SETD2-related disorder, Luscan-Lumish syndrome |
| RS2106770574 |
NDUFAF3
|
Health Risk |
Likely pathogenic |
Mitochondrial complex I deficiency, nuclear type 18 |
| RS2106787058 |
TMIE
|
Health Risk |
Likely pathogenic |
Ear malformation, Ear malformation |
| RS2106802170 |
QRICH1
|
Health Risk |
Conflicting classifications of pathogenicity |
Ververi-Brady syndrome, Ververi-Brady syndrome |
| RS2106809795 |
GBE1
|
Health Risk |
Pathogenic/Likely pathogenic |
Glycogen storage disease IV, classic hepatic |
| RS2106809957 |
GBE1
|
Health Risk |
Pathogenic |
Glycogen storage disease, type IV |
| RS2106810015 |
GBE1
|
Health Risk |
Likely pathogenic |
Glycogen storage disease, type IV |
| RS2106812365 |
QRICH1
|
Health Risk |
Pathogenic |
Ververi-Brady syndrome, Ververi-Brady syndrome |
| RS2106813640 |
QRICH1
|
Health Risk |
Likely pathogenic |
Ververi-Brady syndrome, Ververi-Brady syndrome |
| RS2106814058 |
QRICH1
|
Health Risk |
Pathogenic |
Ververi-Brady syndrome, Ververi-Brady syndrome |
| RS2106854788 |
FOXP1
|
Health Risk |
Pathogenic |
Intellectual disability-severe speech delay-mild dysmorphism syndrome, Intellectual disability-severe speech delay-mild dysmorphism syndrome |
| RS2106854800 |
QRICH1
|
Health Risk |
Likely pathogenic |
Ververi-Brady syndrome, Ververi-Brady syndrome |
| RS2106855069 |
QRICH1
|
Health Risk |
Likely pathogenic |
Ververi-Brady syndrome, Ververi-Brady syndrome |
| RS2106862871 |
QRICH1
|
Health Risk |
Likely pathogenic |
Ververi-Brady syndrome, Ververi-Brady syndrome |
| RS2106862882 |
QRICH1
|
Health Risk |
Likely pathogenic |
Ververi-Brady syndrome, Inborn genetic diseases |
| RS2106863052 |
QRICH1
|
Health Risk |
Pathogenic |
Ververi-Brady syndrome, Ververi-Brady syndrome |
| RS2106863220 |
QRICH1
|
Health Risk |
Pathogenic |
Ververi-Brady syndrome, Ververi-Brady syndrome |
| RS2106863254 |
QRICH1
|
Health Risk |
Likely pathogenic |
Ververi-Brady syndrome, Ververi-Brady syndrome |
| RS2106865 |
ABCC8
|
Health Risk |
Conflicting classifications of pathogenicity |
Leucine-induced hypoglycemia, Hyperinsulinemic hypoglycemia |